Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: In: Cancers (2020) 12:4, 1035. https://doi.org/10.3390/cancers12041035

Event: Veröffentlichung

(where): Würzburg

(who): Universität Würzburg

(when): 2022

Creator: Zhou, Xiang
Flüchter, Patricia
Nickel, Katharina
Meckel, Katharina
Messerschmidt, Janin
Böckle, David
Knorz, Sebastian
Steinhardt, Maximilian Johannes
Krummenast, Franziska
Danhof, Sophia
Einsele, Hermann
Kortüm, Martin
Rasche, Leo

DOI: 10.3390/cancers12041035

URN: urn:nbn:de:bvb:20-opus-203704

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:31 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zhou, Xiang
Flüchter, Patricia
Nickel, Katharina
Meckel, Katharina
Messerschmidt, Janin
Böckle, David
Knorz, Sebastian
Steinhardt, Maximilian Johannes
Krummenast, Franziska
Danhof, Sophia
Einsele, Hermann
Kortüm, Martin
Rasche, Leo
Universität Würzburg

Time of origin

2022

Other Objects (12)

$Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma$

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

$Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma$

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

$Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma$

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

$Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma$

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

$Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma$

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

$Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma$

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

$Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma$

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma

Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns

Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption

VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies

SRT-Server: powering the analysis of spatial transcriptomic data

N4 DNA recognition by STAT6: structural and functional implications

Related objects

Reset password